EA033459B1 - Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций - Google Patents

Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций

Info

Publication number
EA033459B1
EA033459B1 EA201692250A EA201692250A EA033459B1 EA 033459 B1 EA033459 B1 EA 033459B1 EA 201692250 A EA201692250 A EA 201692250A EA 201692250 A EA201692250 A EA 201692250A EA 033459 B1 EA033459 B1 EA 033459B1
Authority
EA
Eurasian Patent Office
Prior art keywords
spp
bacterial infections
fused
treatment
heteroaromatic compounds
Prior art date
Application number
EA201692250A
Other languages
English (en)
Russian (ru)
Other versions
EA201692250A1 (ru
Inventor
Michael Huband
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of EA201692250A1 publication Critical patent/EA201692250A1/ru
Publication of EA033459B1 publication Critical patent/EA033459B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201692250A 2014-05-29 2015-05-27 Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций EA033459B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
EA201692250A1 EA201692250A1 (ru) 2017-06-30
EA033459B1 true EA033459B1 (ru) 2019-10-31

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692250A EA033459B1 (ru) 2014-05-29 2015-05-27 Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Huband M.D. et al.: "In Vitro Antibacterial Activity of AZD0914 and Comparators againt Mycoplasma, Ureaplasma and Chlamydia", INTERNET 6 September 2014 (2014-09-06), XP002749518, Retrieved from the Internet:URL:http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-265.htm [retrieved on 2015-10-30] abstract *
Huband M.D. et al.: "In Vitro Antibacterial Activity of AZD0914: A New Spiropyrimidinetrione Bacterial DNA Gyrase Inhibitor against Potential Agents of Bioterrorism", INTERNET, 6 September 2014 (2014-09-06), XP002749519, Retrieved from the Internet:URL:http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-264.htm [retrieved on 2015-10-30]abstract *
STEPHAN A. KOHLHOFF, MICHAEL D. HUBAND AND MARGARET R. HAMMERSCHLAG: "In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 58, no. 12, 1 December 2014 (2014-12-01), US, pages 7595 - 7596, XP002749516, ISSN: 0066-4804, DOI: 10.1128/AAC.03920-14 *
Waites K.B. et al.: "In Vitro Antibacterial Activity of AZD0914 Against Human Mycoplasmas and Ureaplasmas", INTERNET 25 March 2015 (2015-03-25), XP002749517, Retrieved from the Internet:URL:http://aac.asm.org/content/early/2015/03/24/AAC.04945-14.ful1.pdf [retrieved on 2015-10-30] the whole document *

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
TWI657818B (zh) 2019-05-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
MX365261B (es) 2019-05-27
PH12016502271B1 (en) 2017-02-06
KR20170007818A (ko) 2017-01-20
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
AU2015265620B2 (en) 2020-04-09
SG11201609404SA (en) 2016-12-29
CN106659725A (zh) 2017-05-10
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
IL265757A (en) H1-Imidazo[5,4-b]pyridine-2(h3)-converted ions and their use as glun2b receptor modulators
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
WO2015179441A3 (en) Macrocyclic broad spectrum antibiotics
ZA201103533B (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
CL2015002591A1 (es) Entidades químicas.
BR112017024367A2 (pt) cristais de azabicíclico composto
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2016012997A (es) (5,6-dihidro)pirimido[4,5-e]indolizinas.
MX2016016363A (es) Compuestos que comprenden un sistema de 1,1',2,5'-tetrahidroespiro [indol-3,2'-pirrol]-2,5'-diona como inhibidores de la interaccion de proteina-proteina p53-mdm2.
MX386742B (es) Antibióticos de amplio espectro macrocíclico.
EA201692032A1 (ru) Антибактериальные соединения
HK1248680A1 (zh) 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂
EA033459B1 (ru) Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
MX387476B (es) Antibióticos de amplio espectro macrocíclico.
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
NZ714742A (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
HK40012542A (en) Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators
HK1236127A1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
HK1228395A1 (en) Antibacterial compounds
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU